The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/ajp.131.5.587

Nineteen hyperactive school children were treated in an outpatient clinic with imipramine for eight weeks, followed by four weeks of placebo. On the basis of ratings by a child psychiatrist, parents, and teachers, significant improvement was observed in hyperactivity as well as in defiance, inattentiveness, and sociability. Placebo treatment resulted in deterioration of behavior. The side effects of anorexia and insomnia were reported but represented no serious problem. The unique effects of imipramine and its advantages over central nervous systern stimulants in the treatment of hyperactive children are discussed.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.